We are live on ! Find out more

817 hedge funds and large institutions have $11.1B invested in GSK in 2020 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 246 increasing their positions, 344 reducing their positions, and 109 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital inflows, than outflows

Capital inflows: $1.52B | Capital outflows: $1.32B

7% more call options, than puts

Call options by funds: $105M | Put options by funds: $98.5M

0.17% more ownership

Funds ownership: 11.81% → 11.99% (+0.17%)

1% less funds holding

Funds holding: 825 → 817 (-8)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

28% less repeat investments, than reductions

Existing positions increased: 246 | Existing positions reduced: 344

47% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 109

Holders
817
Holders Change
-8
Holders Change %
-0.97%
% of All Funds
14.39%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.16%
New
58
Increased
246
Reduced
344
Closed
109
Calls
$105​M
Puts
$98.5​M
Net Calls
+$6.61​M
Net Calls Change
-⁠$13.2​M

GSK Hedge Fund Activity: Q4 2020 in Review

817 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2020, worth a combined $11.1B — down 0.73% from $11.2B a quarter earlier.

Sellers outnumbered buyers: 109 funds closed out of GSK and 58 opened new positions — a net loss of 51 holders — while 344 trimmed existing stakes and 246 added.

The largest buyer was Dodge & Cox, adding an estimated $659M. The largest seller was Renaissance Technologies, cutting an estimated $149M.

  • 817 institutional investors held GSK (GSK) as of Q4 2020, down from 825 in Q3 2020.
  • Funds reported $11.1B of GSK stock for Q4 2020, down 0.73% quarter-over-quarter.
  • 58 funds opened new GSK positions in Q4 2020 and 109 closed out, a net change of -51 holders.
  • The largest GSK buyer in Q4 2020 was Dodge & Cox, an estimated $659M added.
  • The largest GSK seller in Q4 2020 was Renaissance Technologies, an estimated $149M sold.

Based on aggregated 13F filings for Q4 2020.